PAVE 0.28ZWS.TO -0.03VMO.TO 0.53ZAP 0.15CAT 1.97AMZN -2.48GL 0.33DAL -1.96
Amgen Inc. (AMGN)

NASDAQ:AMGN

Amgen Inc. (AMGN)

415.21
-2.63 (0.63%)
as of Aug 14, 2026, 8:00:00 pm Market Open.
107 watching
Icon Financials Financials Icon Analysis Technical Analysis
Interactive Chart
1w 1m 6m 1y
0
Investor Insights
star iconAug 15, 2026, 12:00 am

This summary was created by AI, based on 17 opinions in the last 12 months.

Amgen Inc. has garnered a generally positive outlook from analysts, highlighting its strong financial performance and innovative pipeline. The company recently reported impressive earnings, surpassing both top and bottom line expectations, alongside raising its guidance for future performance. Analysts emphasize the promising prospects of its GLP-1 weight loss drug currently in phase 3 testing. With a stable management team and multiple products experiencing double-digit growth, Amgen is considered a robust investment in the biotech sector. The stock is also deemed attractively priced with a good dividend yield, suggesting a solid long-term hold for investors.

consensus icon
Consensus
Positive
valuation icon
Valuation
Undervalued
review icon
Similar
GILD
BUY

Amgen Inc.(AMGN)

May 26, 2003
Has better earnings and price momentum than Biogen going forward. Likes both Biogen and Amgen, but Amgen is their first choice.
Photo of Peter Arender, CFAPeter Arender, CFAUnlock Rating
$61.88

Stock price when the opinion was issued

$415.21

As of Aug 14, 2026. Market Open.

biotechnologypharmaceutical
PAST TOP PICK

Amgen Inc.(AMGN)

May 06, 2003
(Was a top pick on Apr 7. Up 7.4%) Still likes.
Photo of Brian Acker, CABrian Acker, CAUnlock Rating
$60.97

Stock price when the opinion was issued

$415.21

As of Aug 14, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Amgen Inc.(AMGN)

Apr 30, 2003
Three drugs are coming out which are blockbusters.
Photo of Brian Acker, CABrian Acker, CAUnlock Rating
$61.30

Stock price when the opinion was issued

$415.21

As of Aug 14, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Amgen Inc.(AMGN)

Apr 07, 2003
Expects the S&P to drop to 820 and this stock could drop. Buy on pull backs. Has three block buster drugs on the way.
Photo of Brian Acker, CABrian Acker, CAUnlock Rating
$58.41

Stock price when the opinion was issued

$415.21

As of Aug 14, 2026. Market Open.

biotechnologypharmaceutical
BUY ON WEAKNESS

Amgen Inc.(AMGN)

Jan 13, 2003
Very successful biotech. Big growth. May be a little high.
Photo of Neil MurdockNeil MurdockUnlock Rating
$51.52

Stock price when the opinion was issued

$415.21

As of Aug 14, 2026. Market Open.

biotechnologypharmaceutical
BUY ON WEAKNESS

Amgen Inc.(AMGN)

Aug 13, 2002
18/20% growth for the next few years. Would prefer to buy in the $30's.
Photo of Andrew McCreathAndrew McCreathUnlock Rating
$45.64

Stock price when the opinion was issued

$415.21

As of Aug 14, 2026. Market Open.

biotechnologypharmaceutical
HOLD

Amgen Inc.(AMGN)

Jul 03, 2002
The biotech sector is down. A high quality company.
Photo of David BaskinDavid BaskinUnlock Rating
$35.83

Stock price when the opinion was issued

$415.21

As of Aug 14, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Amgen Inc.(AMGN)

Jan 02, 2002
Doesn't like their run at Immunex.
Photo of Brad WillockBrad WillockUnlock Rating
$56.40

Stock price when the opinion was issued

$415.21

As of Aug 14, 2026. Market Open.

biotechnologypharmaceutical
BUY ON WEAKNESS

Amgen Inc.(AMGN)

Dec 28, 2001
A little high now. Would buy at $50.
Photo of Brian Acker, CABrian Acker, CAUnlock Rating
$59.06

Stock price when the opinion was issued

$415.21

As of Aug 14, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Amgen Inc.(AMGN)

Dec 19, 2001
Too expensive.
Photo of Michelle CalpinMichelle CalpinUnlock Rating
$58.33

Stock price when the opinion was issued

$415.21

As of Aug 14, 2026. Market Open.

biotechnologypharmaceutical
BUY

Amgen Inc.(AMGN)

Jul 31, 2001
A good buy and hold. Good products. Volatile.
Photo of Gavin GrahamGavin GrahamUnlock Rating
$62.71

Stock price when the opinion was issued

$415.21

As of Aug 14, 2026. Market Open.

biotechnologypharmaceutical
BUY

Amgen Inc.(AMGN)

Jul 06, 2001
Good broad spectrum. Volatile.
Photo of Glenn Paradis, BA, CFAGlenn Paradis, BA, CFAUnlock Rating
$57.16

Stock price when the opinion was issued

$415.21

As of Aug 14, 2026. Market Open.

biotechnologypharmaceutical
PAST TOP PICK

Amgen Inc.(AMGN)

Jun 06, 2001
(Was a top pick on Feb 22/01 down 3%)Still likes. A good entry point. Likes better than Hemasol.
Photo of John Sinkins, CFAJohn Sinkins, CFAUnlock Rating
$68.20

Stock price when the opinion was issued

$415.21

As of Aug 14, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Amgen Inc.(AMGN)

Feb 22, 2001
Biotechs should grow substantially. A core company in the biotech sector. Has a pipeline. Profitable.
Photo of John Sinkins, CFAJohn Sinkins, CFAUnlock Rating
$70.06

Stock price when the opinion was issued

$415.21

As of Aug 14, 2026. Market Open.

biotechnologypharmaceutical
BUY ON WEAKNESS

Amgen Inc.(AMGN)

Jan 08, 2001
Likes. In late stage production
Photo of Noah Blackstein, B.A., CFANoah Blackstein, B.A., CFAUnlock Rating
$58.69

Stock price when the opinion was issued

$415.21

As of Aug 14, 2026. Market Open.

biotechnologypharmaceutical
Showing 151 to 165 of 166 entries

Build your watch list

Sign in to track investments
you care about

Latest Buy Signals

META -5.12$589.85
NVDA -0.14$225.16
ORCL -5.7$150.52
VEQT.TO -0.23$62.79
VBAL.TO -0.17$40.08

Today's Top Picks

PAVE 0.28$58.59
ZWS.TO -0.03$22.23
VMO.TO 0.53$96.97
ZAP 0.15$33.15
CAT 1.97$856.57

Popular Articles

Latest Sell Signals

QMAX.TO -0.22$25.53
CDZ.TO -0.01$46.94
VFV.TO -1.06$191.64
HTA.TO -0.14$22.93
ZEB.TO 0.38$78.29

Most Recent Experts

Bill Baruch, Founder, Blue Line Capital

Bill Baruch, Founder, Blue Line Capital

Blue Line Capital

Richard Orrell

Richard Orrell

RN Croft Financial Group

Stan Wong

Stan Wong

Private Wealth Management, ScotiaMcleod

The Panic-Proof Portfolio (Stockchase Research)

The Panic-Proof Portfolio (Stockchase Research)

Stockchase Premium

The Weekly Buzzing Stocks by Billy Kawasaki

The Weekly Buzzing Stocks by Billy Kawasaki

Stockchase

disclaimer

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at: [email protected].

About usHow to useContact Us
More...
AdvertisingIn the newsPrivacy PolicyTerms of service
FacebookX
© 2000 - 2026 Stockchase Inc. by Wealthica
The ultimate 360° Tracker Your financial life in one place, automatically

You may also like